Biophytis Sa (BPTSY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biophytis (BPTSY) has launched a Phase 2 study titled “A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in Reducing the Muscle Strength Loss From the GLP1 Agonist Semaglutide in Combination With Dieting in Obese and Overweight Adult Patients (OBA).” The trial aims to see if its oral drug BIO101 can protect muscle strength in adults using semaglutide for weight loss, a key concern as GLP-1 drugs go mainstream.
The main treatment under study is BIO101, an oral capsule containing 20-hydroxyecdysone, a plant-derived compound designed to preserve or improve muscle strength. All participants also receive semaglutide, already a leading GLP-1 weight loss drug, along with diet changes, so the study tests whether adding BIO101 can offset muscle loss without adding new safety issues.
The trial is an interventional Phase 2 study with patients randomly assigned to BIO101 or placebo in parallel groups. It is double-blind, meaning neither patients nor doctors know who gets the active drug, and the main goal is treatment focused, looking at changes in muscle strength and overall physical function during semaglutide-based weight loss.
The study was first submitted on Feb. 3, 2026, and is listed as “not yet recruiting,” signaling that sites are preparing to enroll patients. The most recent update was filed on Feb. 11, 2026, which tells investors the program is active at the planning stage, though primary and final completion dates have not yet been reported.
For investors, this update highlights Biophytis’ attempt to position BIO101 as a muscle-protection add-on to blockbuster GLP-1 drugs used by Novo Nordisk and Eli Lilly. A successful readout could open a niche, combo-style market, support Biophytis’ valuation, and draw interest from larger partners, but the early stage, small-cap status, and clinical risk mean sentiment may stay speculative until recruitment and early data milestones are clearer.
The study is currently in the set-up phase and remains listed as ongoing on ClinicalTrials.gov, where further details and future updates will be available.
To learn more about BPTSY’s potential, visit the Biophytis Sa drug pipeline page.